588. Seroconversion Among Adults After Receiving At Least One Dose of a COVID-19 Vaccine: COVID-19 Community Research Partnership, Mid-Atlantic, Southeast and Southern United States, December 2020-May 2021

BACKGROUND: Well-regulated clinical trials have shown authorized COVID-19 vaccines to be immunogenic and highly efficacious. Information about antibody responses after vaccination in real-world settings is needed. METHODS: We evaluated seroconversion rates in adults reporting ≥ 1 dose of an authoriz...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedman-Klabanoff, DeAnna J, Tjaden, Ashley, Santacatterina, Michele, Munawar, Iqra, Sanders, John W, Herrington, David M, Wierzba, Thomas F, Berry, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644496/
http://dx.doi.org/10.1093/ofid/ofab466.786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644496/
http://dx.doi.org/10.1093/ofid/ofab466.786

Ejemplares similares